10-Q quarterly report · filed Nov 4, 2026

PRECIGEN, INC. (PGEN) Q3 2026 10-Q Quarterly Report

Short answer

PRECIGEN, INC. (PGEN) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $74M with net income of $36M.

Q3 2026 key financials · XBRL

Revenue
$74M
+34.9% QoQ
Net income
$36M
+124.4% YoY · +78.2% QoQ
Operating margin
52.1%
EPS (diluted)
$0.09
+108.3% YoY · +80.0% QoQ

Source: XBRL data from the PRECIGEN, INC. (PGEN) Q3 2026 10-Q on SEC EDGAR. USD.

PRECIGEN, INC. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $74.1M, up >200% YoY from $2.9M, driven by Papzimeos product revenue of $72.9M
  • Operating margin 52.1% vs (1,180.4)% YoY, with operating income $38.7M vs loss of $34.5M
  • Papzimeos strongest product line, $72.9M revenue; collaboration and licensing revenue weakest, $0 vs $1.8M YoY
  • Q3 operating cash flow $11.9M positive; September 30 cash $15.0M plus investments of $36.0M
  • Outlook: continued Papzimeos commercialization, with headwinds from 127-day customer payment terms and potential additional capital needs

Risk Factors

  • No additional material risk-factor changes since the Annual Report
  • Carried-forward risks may materially affect operating results
  • Carried-forward risks may materially affect financial condition
  • SEC filings contain additional relevant risk disclosures

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other PRECIGEN, INC. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.